John Murphy: DOLLAR RISE HURTS STOCKS AND COMMODITIES — STOCK VOLUME PATTERN TURNS NEGATIVE — NASDAQ AND S&P 500 NEAR POINT & FIGURE SELL SIGNALS — BEAR FUND TURNS UP
I wrote a week ago about the U.S. Dollar Index starting to bounce from major support formed in the spring of 2008 near 22 and an oversold condition. I warned that a dollar rally could unsettle...
October 30, 2009 | Filed Under Analyst Opinions | Leave a Comment
e-Rewards, Inc. Reaches Agreement on the Terms of a Recommended Acquisition of Research Now PLC
DALLAS, TX--(Marketwire - October 23, 2009) - e-Rewards, Inc., the United States' largest online market research panel provider, today announced it has reached an agreement on the terms of a Recommended Acquisition of Research Now PLC, one of the research industry's leading international online fieldwork and panel firms. Research Now, an independent public company listed on the AIM market of the London Stock Exchange, will become a wholly owned subsidiary of e-Rewards, Inc. upon completion of the transaction.
October 23, 2009 | Filed Under Mergers and Acquisitions | Leave a Comment
NuMobile, Inc. Announces Letter of Intent to Acquire SecurAct, Inc. to Add Identity Management Software to Growing Portfolio of Smartphone and Mobile Computing Solutions
CARY, NC--(Marketwire - October 23, 2009) - NuMobile, Inc. (
October 23, 2009 | Filed Under Mergers and Acquisitions | Leave a Comment
Electrical Products
The U.S. Electrical Products industry is highly fragmented, with the largest suppliers together accounting for only a small percentage of total sales.
October 23, 2009 | Filed Under Analyst Opinions | Leave a Comment
U.S. Banks
The banking system is not yet out of the woods, as there are persistent problems that need to be addressed by the government before shifting the strategy to growth.
October 23, 2009 | Filed Under Analyst Opinions | Leave a Comment
Medical Devices
The Healthcare IT landscape has changed since the Obama Administration passed a health care stimulus package to encourage hospitals and physicians practices to modernize their health record keeping.
October 23, 2009 | Filed Under Analyst Opinions | Leave a Comment
Cytori Therapeutics (CYTX)
We continue to be very positive on Cytori Therapeutics (<a href=http://www.zacks.com/stock/quote/cytx>CYTX</a>) and believe the company's Celution System, a better mousetrap for quickly and efficiently harvesting adult stem cells, will see sales ramp significantly over the next few years. <p> Sales of the system have been tracking with our expectations. Ultimately, the clinical data will determine the pace at which the ramp continues. So far, the clinical data has been exciting, and with several investigator-sponsored programs ongoing. Additional data expected over the next few years will have an immediate impact on the financial results. <p> Today's price represents a very attractive entry point in our view. We are maintaining our Outperform rating and $8 target.
October 23, 2009 | Filed Under Stock Picks | Leave a Comment
Pozen, Inc. (POZN)
Pozen, Inc. (<a href=http://www.zacks.com/stock/quote/pozn>POZN</a>) is one of our top-picks for small-cap biotech. We see the fundamentals as strong and the valuation as low. <p> We are pleased to see the NDA for Vimovo (PN-400) filed and now accepted by the U.S. FDA. FDA acceptance earned Pozen a $10 million milestone from AstraZeneca in August. We expect sales of Treximet to ramp in the coming quarters now that the groundwork has been laid. And finally, phase III trials on the very exciting PA program should start in the fall. <p> The company is financially well positioned and fundamentally strong with respect to the pipeline. We recommend being buyers at this level.
October 23, 2009 | Filed Under Stock Picks | Leave a Comment
Vodafone Group, Plc (VOD)
We maintain our Outperform recommendation for Vodafone (<a href=http://www.zacks.com/stock/quote/vod>VOD</a>), the largest revenue generating international wireless carrier. Revenue growth in the last quarter was fuelled by foreign exchange gains and acquisitions. <p> Additionally, increase in subscriber base was driven by continued healthy net additions in its Indian operation. Vodafone's globally diversified operation provides hedging elements which offset price competition and translation risk that may arise in specific markets. The company continues to accelerate 3G wireless service deployments and expanding network availability across Asia, Eastern Europe and Africa. <p> Moreover, Vodafone is focused on improving shareholder returns through attractive dividend payouts. Management's outlook for fiscal 2010 remains favorable as operating results are expected to improve with continued growth across incipient markets coupled with ongoing cost saving initiatives and currency exchange translation gains.
October 23, 2009 | Filed Under Stock Picks | Leave a Comment
Gentiva Health Services (GTIV)
Gentiva Health Services, Inc. (<a href=http://www.zacks.com/stock/quote/gtiv>GTIV</a>) has scheduled its third quarter earnings call for October 29th, one week from today. Gentiva reported a second-quarter net income of 59 cents per share which was much higher than the Zacks Consensus Estimate of 45 cents. <p> The company boasts of a diversified product portfolio. Its product offerings include home health, hospice, respiratory therapies and home medical equipment. Gentiva serves nearly 500,000 patients annually in more than 380 locations across 39 states. Gentiva has successfully grown primarily through acquisitions. During the past few years, the company has completed multiple acquisitions which have expanded its reach further. <p> Gentiva continues to look for profitable acquisitions. We have an Outperform rating on the stock.
October 23, 2009 | Filed Under Stock Picks | Leave a Comment